Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Tedizolid phosphate (Sivextro®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinione antibacterial. Treatment should only be initiated on advice from local microbiologists or specialists in infectious diseases. Tedizolid phosphate (Sivextro®) is not recommended for use within NHS Wales outside of this subpopulation/circumstance. |
|||
|
|||
Medicine details |
|||
| Medicine name | tedizolid phosphate (Sivextro®) | ||
| Formulation | 200 mg film-coated tablet; 200 mg powder for concentrate for solution for infusion | ||
| Reference number | 1607 | ||
| Indication | Treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinione antibacterial |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 3415 | ||
| NMG meeting date | 07/10/2015 | ||
| AWMSG meeting date | 11/11/2015 | ||
| Ratification by Welsh Government | 09/12/2015 | ||
| Date of issue | 10/12/2015 | ||
| Date of last review | 02/04/2019 | ||